Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Anxiety Disorders 1Adjustment Disorders 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × N-Methyl-3,4-methylenedioxyamphetamine × Clear all
NCT05584826 2026-05-04

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Sunstone Medical

Phase 2 Recruiting
20 enrolled

Adjustment Disorders, Neoplasms

NCT00252174 2017-11-14

MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

Brigham and Women's Hospital

Phase 2 Terminated
2 enrolled 6 charts

Anxiety Disorders, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡